How to Help Your Patients Save Money on Doptelet: A Provider's Guide to Savings Programs

For hematologists, hepatologists, and other providers prescribing Doptelet (avatrombopag), cost is one of the most frequent access barriers your patients will encounter. With a wholesale acquisition cost of approximately $12,657 for 30 tablets (as of January 2025), the financial burden is significant — particularly for patients on long-term ITP therapy who require monthly refills. This guide covers every tool available to help your patients afford Doptelet.

Understanding Doptelet Pricing: What Your Patients Actually Pay

The WAC (wholesale acquisition cost) published by Sobi as of January 2025 is:

10 tablets: ~$4,219

15 tablets (60 mg daily dose carton for CLD): ~$6,329

30 tablets (standard monthly ITP supply at starting dose): ~$12,657

Most patients do not pay WAC. What they actually pay depends on insurance coverage, their specific plan benefits (tier, deductible, copay), and the financial assistance programs they qualify for. Your staff's role is to ensure every eligible patient is enrolled in the most appropriate savings program before their first fill.

Program 1: Doptelet Connect Copay Assistance (Commercially Insured Patients)

Sobi's Doptelet Connect program, managed by AssistRx, includes a copay assistance program for patients with commercial insurance. This can substantially reduce the out-of-pocket copay for Doptelet. Key program details for your practice:

Eligibility: Commercially insured patients with an approved on-label Doptelet indication (ITP or CLD).

Not eligible: Patients covered by Medicare, Medicaid, TRICARE, Veterans Affairs, or other government programs.

Enrollment: Completed as part of the Doptelet Connect prescription enrollment form. The specialty pharmacy processes copay enrollment simultaneously with the PA.

Contact: DopteletConnect@AssistRx.com or 1-855-686-8729.

Program 2: Free Trial Offer for New ITP Patients

For patients who are new to Doptelet therapy and have ITP, Sobi offers a free trial offer through Doptelet Connect. This allows eligible patients to receive an initial supply at no cost while waiting for insurance approval or during the transition to their permanent copay arrangement. Eligibility requirements include:

New to Doptelet therapy (no prior Doptelet prescriptions)

Age 18 or older

Prescribed for ITP only (not the CLD indication)

Under care of a licensed prescriber in the US

Not cash-pay patients; cannot be reimbursed by government programs

Program 3: Patient Assistance Program (Uninsured and Underinsured)

For patients who lack insurance or have insufficient coverage to afford Doptelet, Doptelet Connect administers a patient assistance program (PAP). Eligibility is based on financial need and insurance status. Your team should proactively screen for PAP eligibility at the start of the prescription process for uninsured or underinsured patients — don't wait for the patient to ask.

Program 4: Medicare Part D Changes in 2025–2026

Several Medicare reforms enacted as part of the Inflation Reduction Act significantly change the cost picture for Medicare patients on high-cost specialty drugs like Doptelet:

$2,000 annual out-of-pocket cap (effective 2025): Medicare Part D out-of-pocket spending is now capped at $2,000 per year. Given Doptelet's high cost, patients who have commercial or Part D coverage can reach this cap relatively quickly, after which their plan covers 100% of drug costs for the remainder of the year.

Medicare Prescription Payment Plan: Allows patients to spread out-of-pocket costs monthly rather than paying a large upfront amount. Especially helpful for patients who fill Doptelet early in the calendar year.

Extra Help (Low Income Subsidy): Medicare patients meeting income and asset limits can receive Extra Help, which dramatically reduces Part D premiums, deductibles, and copays. All qualifying Medicare patients should be screened for Extra Help eligibility.

Practical Workflow: Integrating Savings Programs Into Your Doptelet Prescribing Process

Consider embedding the following steps into your standard Doptelet initiation workflow:

At prescription decision: Identify insurance type (commercial, Medicare, Medicaid, uninsured).

Submit Doptelet Connect enrollment form with all required clinical documentation.

Ensure new ITP patients are flagged for the free trial offer.

Screen uninsured/underinsured patients for PAP eligibility.

For Medicare patients: discuss $2,000 cap, Prescription Payment Plan, and Extra Help screening.

Follow up with patient and specialty pharmacy within 1 week of submission to confirm PA status.

When to Escalate: Contacts for Reimbursement Issues

For complex coverage issues, PA denials, or step therapy appeals related to Doptelet, escalate through:

Field reimbursement manager: Email Doptelet.escalation@sobi.com with your practice name, contact name, phone, state, and ZIP code.

Doptelet Connect: Fax: 1-855-686-8729; Email: DopteletConnect@AssistRx.com

Sobi patient services: 1-855-454-3887

For help identifying dispensing locations when a patient's pharmacy is delayed, use medfinder for providers. For access and shortage context, see: Doptelet Shortage: What Providers and Prescribers Need to Know in 2026.